MarketCap
Facebook
X
TelegramAnnual report 2026
added 02-10-2026
Exelixis Operating Cash Flow 2011-2026 | EXEL
Annual Operating Cash Flow Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 884 M | 700 M | 333 M | 363 M | 401 M | 527 M | - | 416 M | 166 M | 206 M | -142 M | -235 M | -199 M | -123 M | -159 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 884 M | -235 M | 224 M |
Quarterly Operating Cash Flow Exelixis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 211 M | - | - | - | 68.8 M | - | - | - | 84.4 M | - | 289 M | 179 M | 148 M | - | 304 M | 221 M | 39.5 M | - | 176 M | 158 M | 56.1 M | - | 369 M | 293 M | 162 M | - | 311 M | 146 M | 71.8 M | - | 112 M | 74.4 M | 68.9 M | - | 125 M | 131 M | 157 M | - | -106 M | -71.9 M | -45.1 M | - | -185 M | -127 M | -72.1 M | - | -151 M | -94.4 M | -54.4 M | - | -84.4 M | -50.4 M | -15 M | - | -130 M | -86.8 M | -43.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 369 M | -185 M | 67.6 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.41 | -1.4 % | $ 2.57 B |  USA |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.79 | -6.51 % | $ 4.31 M |  China |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 165.07 | -0.79 % | $ 8.21 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.76 | -1.7 % | $ 1.12 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.57 | -1.83 % | $ 1.4 B | Britain |
 |
Corvus Pharmaceuticals
CRVS
|
-23.9 M | $ 18.11 | 1.23 % | $ 870 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-25.6 M | $ 26.36 | -1.82 % | $ 706 M | USA |
 |
Certara
CERT
|
96.3 M | $ 7.24 | 2.62 % | $ 1.16 B | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-49.4 M | $ 1.01 | -0.98 % | $ 74.1 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 23.77 | -0.46 % | $ 2.91 B | USA |
 |
Agenus
AGEN
|
-224 M | $ 3.27 | -2.09 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-373 M | $ 28.85 | -1.2 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
7.39 M | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.71 | -2.43 % | $ 116 M | France |
 |
Alector
ALEC
|
-184 M | $ 2.13 | -3.39 % | $ 219 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-79.8 M | $ 4.22 | 1.32 % | $ 300 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
6.73 M | $ 14.3 | 2.66 % | $ 5.93 B |  Irlanda |
 |
AbbVie
ABBV
|
19 B | $ 233.44 | -0.33 % | $ 413 B | USA |